Bladder Cancer

New Reference: Neoadjuvant CISplatin and Gemcitabine for Urothelial Cancer

2023-03-15

  • Study

    Multicenter, single-arm, phase II trial
    Localized high-grade UTUC or radiographically visible invasive disease
    Four cycles of split-dose GC (n=57)

  • Efficacy

    Pathologic response rate: 63% (37 of 57 pts)
    Complete response rate: 19% (11 of 57 pts)
    2-year PFS: 89% [81-98], 5-year PFS: 72% [59-87]
    2-year OS: 93% [86-100], 5-year OS: 79% [67-94]

  • Safety

    Grade 3 AEs: Neutropenia (33%), febrile neutropenia (7.0%), thrombocytopenia (7.0%), creatinine increased (5.3%)


    • J Clin Oncol 2023: 05 JAN

    Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma

    http://doi.org/10.1200/JCO.22.00763

    Reviewed by Elvin Chalabiyev, MD on Mar 15, 2023